 This study is open to patients with advanced cancers where tumour samples that were previously removed are shown to express the Lewis-y antigen. A series of tests will be performed to determine eligibility to participate in the trial. Groups of patients will be allocated increasing doses of CMD-193 at study entry to explore the effects in a series of doses. 